Dana-Farber Cancer Institute presents potentially practice changing results from the phase 3 ASCENT-04/KEYNOTE-D19 clinical trial at American Society of Clinical Oncology (ASCO) annual meeting

May 31, 2025 — A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free survival (PFS) compared to avelumab alone in patients with advanced cutaneous squamous cell carcinoma (cSCC). The results, presented as an oral abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, and published in the Journal of Clinical Oncology, suggest a promising new approach for patients with this aggressive form of skin cancer.

COLUMBUS, Ohio – Pancreatic cancer blood tests, genetic predictors of breast cancer survival and sarcoma treatment response prediction tools are among the research topics being presented by scientists from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held from May 30-June 3 in Chicago.

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30-June 3, in Chicago.

Miskov-Zivanov's novel approach and the development of an automated system that leverages AI and knowledge graphs to design more effective lymphocytes, she hopes to transform the design of life-saving immunotherapies.

A new study by investigators from Mass General Brigham showed that a new app they created can help improve the quality of life for caregivers of patients undergoing bone marrow transplant (BMT). The researchers conducted a randomized clinical trial and found that caregivers assigned to use the app showed significantly greater improvements in quality of life, burden, and mood symptoms compared to those who did not have the app. They detailed their findings in a presentation at the American Society of Clinical Oncology annual meeting and a paper simultaneously published in the Journal of Clinical Oncology.